Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06825871 · ClinicalTrials.gov registry record · NA
Automated Inhaler Monitoring for Asthma Medication Usage
A NA study of Asthma, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT06825871: Recruiting NA study of Asthma, sponsored by Boston Children's Hospital.
NCT06825871 is a NA study of Asthma that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 26 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06825871, a NA study of Asthma, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the aflo™ digital platform's ability to improve inhaler use technique and asthma control for children, adolescents, and adults with uncontrolled asthma. The main questions the trial aims to answer are: 1. Does the platform improve medication adherence and inhaler technique, as measured by the Inhaler Proficiency Score (IPS)? 2. Does the aflo™ platform improve asthma control, as measured by changes in the Asthma Control Test (ACT) and lung function tests (FEV1, PEF)? Participants will: * Use the aflo™ sensor with their asthma inhaler to receive real-time feedback on technique and medication adherence reminders. * Track asthma symptoms and quality of life through a mobile app. * Complete assessment visits and surveys at the start and end of the 3-month study and 2 interim asthma assessment phone calls.
Primary Outcome
Inhaler Proficiency Score (IPS) is a validated, composite score that assesses the accuracy and consistency of inhaler technique, including steps such as inhaler preparation, actuation timing, inhalation depth, and breath hold. Scores range from 0 to 10, with higher scores indicating greater inhaler technique proficiency. Scores will be recorded at baseline and again after 3 months of using the Aflo™ digital platform, which provides step-by-step guidance and real-time feedback on inhaler techniqu
Conditions Studied
Interventions
- DEVICE Smart Inhaler Monitoring Platform for Asthma Management
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06825871 shows while recruiting
NCT06825871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Smart Inhaler Monitoring Platform for Asthma Management is the first listed.
NCT06825871 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06825871 about?
NCT06825871 is a clinical study titled "Automated Inhaler Monitoring for Asthma Medication Usage". The goal of this clinical trial is to evaluate the aflo™ digital platform's ability to improve inhaler use technique and asthma control for children, adolescents, and adults with uncontrolled asthma. The main questions the trial aims to answer are: 1. Does the platform improve medication adherence ...
What is the current status of trial NCT06825871?
This trial is currently recruiting. It is a NA study. The enrollment target is 26 participants. The study started on 2025-12-15. Estimated completion is 2026-06.
What conditions does trial NCT06825871 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06825871?
The interventions under investigation include: Smart Inhaler Monitoring Platform for Asthma Management (DEVICE).
Who is sponsoring clinical trial NCT06825871?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06825871 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06825871's enrollment target sits among peer trials
26 316th of 374 higher than 58 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
ASTHMAXcel Voice Study
RECRUITING · NA
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Asthma and Technology in Emerging African American Adults
RECRUITING · NA
-
BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma
RECRUITING · NA
-
Inhaler Trainer Efficacy Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI